| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | K | | | | | | | | | | | | THE OPHTHALMOLOGY MEDICINES COMPANY | | | | | | | | | | | Corporate Presentation | | | | | | | | | | | March 2023 | | | | | | | | KODIAK Our 24 / 7 / 365 KODIAK in the real world as in published clinical studies, because frequent dosing is no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State or o ...

| --- | --- | |---------------------------------------------------------------------------------------------------------|-------| | | | | | | | KSI-301 Anti-VEGF Antibody Biopolymer Conjugate for Retinal Vein Occlusion: | | | Primary 24-Week Efficacy and Safety Outcomes of the BEACON Phase 3 Pivotal Study | | | Arshad M. Khanani, M.D., M.A., FASRS Director of Clinical Research, Sierra Eye Associates, Reno, NV USA | | | on behalf of the BEACON Study Group | | 2 September 2022 Disclosures | --- | --- | |----- ...

NASDAQ: KOD KODIAK.COM | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | KO | | | | | | | | | | | THE OPHTHALMOLOGY MEDICINES COMPANY | | | | | | | | | | Corporate Presentation | | | | | | | | | | August 2022 | | | | | | | | --- ...

KODIAK.COM NASDAQ: KOD THE OPHTHALMOLOGY MEDICINES COMPANY January 2022 1 S P E C I A L N O T E R E G A R D I N G | --- ...

NASDAQ: KOD KODIAK.COM | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|---------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | THE OPHTHALMOLOGY MEDICINES COMPANY | | | | | | | | | | Barclays Global Healthcare Conference M arch 10, 2 02 1 | | | | | | | 2 | --- ...

NASDAQ: KOD KODIAK.COM | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|--------------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | THE OPHTHALMOLOGY MEDICINES COMPANY | | | | | | | | | | | | | | | | | | | | J.P. Morgan Annual Healthcare Conference Jan uary 11, 2 02 1 | | | | | | | 2 | --- ...

NASDAQ: KOD KODIAK.COM | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------------------------------------|--------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | THE OPHTHALMOLOGY MEDICINES COMPANY | | | | | | | | | | | | | | | | | | | | | Corporate Presentation S ep t ember 2 02 0 | | | | | | 2 | --- ...

Extended Durability in Exudative Retinal Diseases Using the Novel Intravitreal Anti-VEGF Antibody Biopolymer Conjugate KSI-301 1 Update from Phase 1b Study in Patients with wAMD, DME and RVO Mark R. Barakat, MD Retinal Consultants of Arizona Phoenix, AZ American Society of Retina Specialists 2020 July 10, 2020 Disclosures 2 ▪ Financial: AlconC Kodiak SciencesC AllegroC GenentechBC AllerganC NovartisBC AlimeraC NeuBaseS Bausch and LombC Ocular TherapeutixC Clearside BiomedicalC OxurionS EyePoint Pharmaceutic ...

Kodiak Sciences Inc. (NASDAQ:KOD) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants John Borgeson - Chief Financial Officer Victor Perlroth - Chairman and Chief Executive Officer Jason Ehrlich - Chief Medical Officer and Chief Development Officer Conference Call Participants Matthew Bannon - JPMorgan Chase & Co. Michael Yee - Jefferies Financial Group, Inc. Maxwell Skor - Morgan Stanley John McNeil - Goldman Sachs & Co. LLC Robyn Karnauskas - SunTrust Robinson Humphrey, Inc. Gena ...